Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
By I. Pavord, Stephanie Korn, P. Howarth, E. Bleecker, R. Buhl, O. Keene, Hector Ortega, P. Chanez. The Lancet, 2012
1,902 citations recorded by the source corpus.
Subfields: Physiology, Pulmonary and Respiratory Medicine, Sociology and Political Science
View Paper: https://www.semanticscholar.org/paper/35785d2a0028de70a1f7f37da1345ff5b243773a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Pulmonary and Respiratory Medicine
In Sociology and Political Science
Citations in the corpus
- A summary of the new GINA strategy: a roadmap to asthma control (2015, background): “…reduction in the risk of exacerbations from untreated airway inflammation; and newer regimens or treatments such as ICS/ formoterol maintenance and reliever therapy [25] and anti-interleukin (IL)-5 [26] reduce exacerbation risk with little difference from comparators in levels of symptom control.”